Capital expenditure decreased 100.0%
Capital expenditure changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Cash & equivalents changed +275.1% from the comparable as-filed period.
Free-cash-flow proxy changed -156.5% from the comparable as-filed period. The change ranks at the 43th percentile of 7 prior comparable changes.
Net income changed -47.8% from the comparable as-filed period.
Operating cash flow changed -149.5% from the comparable as-filed period. The change ranks at the 43th percentile of 7 prior comparable changes.
Operating income changed -47.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +97.7% from the comparable as-filed period. The change ranks at the 57th percentile of 7 prior comparable changes.
Research & development changed +0.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.